EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Cancer screening with multicancer detection tests: A translational science review

Wendy S Rubinstein iD, Christos Patriotis iD, Anthony Dickherber iD, Paul K J Han iD, Hormuzd A Katki iD, Elyse LeeVan iD, Paul F Pinsky iD, Philip C Prorok iD, Amanda L Skarlupka iD, Sarah M Temkin iD, Philip E Castle iD, Lori M Minasian iD

CA: A Cancer Journal for Clinicians · 2024-07 · 74 (4) · 368-382

DOI: 10.3322/caac.21833 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift CA: A Cancer Journal for Clinicians, online erschienen am 22.03.2024. Verfasst von Wendy S Rubinstein und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Prevention, US National Cancer Institute, Rockville, Maryland, USA. Hauptthemen laut MEDLINE: Neoplasms, Early Detection of Cancer. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Intramural NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multicancer detection (MCD) tests use a single, easily obtainable biospecimen, such as blood, to screen for more than one cancer concurrently. MCD tests can potentially be used to improve early cancer detection, including cancers that currently lack effective screening methods. However, these tests have unknown and unquantified benefits and harms. MCD tests differ from conventional cancer screening tests in that the organ responsible for a positive test is unknown, and a broad diagnostic workup may be necessary to confirm the location and type of underlying cancer. Among two prospective studies involving greater than 16,000 individuals, MCD tests identified those who had some cancers without currently recommended screening tests, including pancreas, ovary, liver, uterus, small intestine, oropharyngeal, bone, thyroid, and hematologic malignancies, at early stages. Reported MCD test sensitivities range from 27% to 95% but differ by organ and are lower for early stage cancers, for which treatment toxicity would be lowest and the potential for cure might be highest. False reassurance from a negative MCD result may reduce screening adherence, risking a loss in proven public health benefits from standard‐of‐care screening. Prospective clinical trials are needed to address uncertainties about MCD accuracy to detect different cancers in asymptomatic individuals, whether these tests can detect cancer sufficiently early for effective treatment and mortality reduction, the degree to which these tests may contribute to cancer overdiagnosis and overtreatment, whether MCD tests work equally well across all populations, and the appropriate diagnostic evaluation and follow‐up for patients with a positive test.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsEarly Detection of CancerHumansTranslational Research, BiomedicalSensitivity and SpecificityMass Screening

Stichwörter der Autor:innen

clinical trialshealth disparitieshematology/medical oncologypathology and laboratory medicinescreening and early detection

Autor:innen und Institutionen

  • Division of Cancer Prevention, US National Cancer Institute, Rockville, Maryland, USA.
  • Center for Strategic Scientific Initiatives, US National Cancer Institute, Rockville, Maryland, USA.
  • Division of Cancer Control and Population Sciences, US National Cancer Institute, Rockville, Maryland, USA.
  • Division of Cancer Epidemiology and Genetics, US National Cancer Institute, Rockville, Maryland, USA.
  • National Institutes of Health Office of Research on Women's Health, Bethesda, Maryland, USA.

ORCID-Profile: Wendy S Rubinstein, Christos Patriotis, Anthony Dickherber, Paul K J Han, Hormuzd A Katki, Elyse LeeVan, Paul F Pinsky, Philip C Prorok, Amanda L Skarlupka, Sarah M Temkin, Philip E Castle, Lori M Minasian

Förderung

  • Intramural NIH HHS

Zitieren

APA

Rubinstein, W. S., Patriotis, C., Dickherber, A., Han, P. K. J., Katki, H. A., LeeVan, E., Pinsky, P. F., Prorok, P. C., Skarlupka, A. L., Temkin, S. M., Castle, P. E., & Minasian, L. M. (2024). Cancer screening with multicancer detection tests: A translational science review. CA: A Cancer Journal for Clinicians, 74(4), 368-382. https://doi.org/10.3322/caac.21833

Vancouver

Rubinstein WS, Patriotis C, Dickherber A, Han PKJ, Katki HA, LeeVan E, et al. Cancer screening with multicancer detection tests: A translational science review. CA: A Cancer Journal for Clinicians. 2024;74(4):368-382. doi:10.3322/caac.21833

BibTeX
@article{Rubinstein2024,
  author = {Rubinstein, Wendy S and Patriotis, Christos and Dickherber, Anthony and Han, Paul K J and Katki, Hormuzd A and LeeVan, Elyse and Pinsky, Paul F and Prorok, Philip C and Skarlupka, Amanda L and Temkin, Sarah M and Castle, Philip E and Minasian, Lori M},
  title = {Cancer screening with multicancer detection tests: A translational science review},
  journal = {CA: A Cancer Journal for Clinicians},
  year = {2024},
  volume = {74},
  number = {4},
  pages = {368--382},
  doi = {10.3322/caac.21833}
}
Kostenlos starten →